Aldoss, I., Issa, G., Blachly, J., Thirman, M., Mannis, G., Arellano, M., DiPersio, J., Traer, E., Zwaan, C., Shukla, N., Cuglievan, B., Grove, C., Greenwood, M., McMahon, C., Perl, A., Stone, R., Papayannidis, C., Dickens, D., Heiblig, M., Zucenka, A., Montesinos, P., Mantzaris, I., Kovacsovics, T., Shami, P., Yu, L., Bagley, R., Smith, A. R., Stein, E. (2025). Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study. Blood. https://doi.org/10.1182/blood-2025-1001